

**Breast Cancer Therapeutics Market - Global Industry Size, Share, Trends,  
Opportunity and Forecast, 2017-2027**

**Segmented By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others), By (Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others), By Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others), By Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), and By Region**

Market Report | 2022-07-01 | 75 pages | TechSci Research

**AVAILABLE LICENSES:**

- Single User License \$4900.00
- Multi-User License \$5900.00
- Custom Research License \$8900.00

**Report description:**

The global breast cancer therapeutics market is expected to grow at an impressive CAGR in the forecast period, 2023-2027. Growing geriatric population susceptible to several chronic illnesses such as cancer is propelling the growth of the global breast cancer therapeutics market.

Breast cancer incidence and prevalence rates are expected to rise globally, boosting the global breast cancer therapeutics market. As a result, significant investment in research and development activities and technological advancements in cancer biology and pharmacology promote breast cancer therapeutics. Continuous advancements aid in the molecular understanding of breast cancer, and the introduction of novel solutions have reduced breast cancer mortality rates in recent years. Newly

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

developed therapeutics effectively slow cancerous cell growth and proliferation, which is projected to boost the global breast cancer therapeutics market in the coming years.

The rising global prevalence of breast cancer and increasing demand for effective treatments for a large number of patients are expected to drive growth in the breast cancer therapeutics market. Breast cancer is one of the most common types of cancer worldwide, and improved diagnostic solutions are expected to drive market growth. Because of the numerous benefits of preventive care and early treatment, individuals sought diagnostic procedures, fueling the global breast cancer therapeutics market growth.

The global breast cancer therapeutics market is expected to grow as a result of government breast cancer screening initiatives and supportive programmes introduced by public organisations. According to the WHO report, early detection of breast cancer helps to reduce breast cancer mortality and increases the survival rate among patients with breast cancer. Many governments around the world encourage people to get screened for breast cancer, particularly women over the age of 50. Screening initiatives and public awareness campaigns are expected to increase the use of drugs for the effective treatment of breast cancer, propelling the global breast cancer therapeutics market growth over the forecast period.

The global breast cancer therapeutics market is segmented into type, end users, and regional distribution. Based on the type, the market is divided into chemotherapy, hormone therapy, immunotherapies, targeted therapy, and others. The targeted therapy is anticipated to register the highest growth in the global breast cancer treatment market, owing to emergence of personalized approach to improve clinical outcomes. Besides, developments in the treatment of metastatic hormone receptor-positive breast cancer have further accelerated the utilization of target-based therapies.

Key players operating in the global breast cancer treatment market are Novartis AG, Pfizer Inc., Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc., Bristol-Myers Squibb Company, Halozyme Inc., Eisai Co., Ltd., Fresenius Kabi AG, among others.

Years considered for this report:

Historical Years: 2017-2020

Base Year: 2021

Estimated Year: 2022

Forecast Period: 2023-2027

Objective of the Study:

- To analyze the historical growth in the market size of the global breast cancer therapeutics from 2017 to 2021.
- To estimate and forecast the market size of global breast cancer therapeutics market from 2023 to 2027 and growth rate until 2027.
- To classify and forecast the global breast cancer therapeutics market based on therapy, end user, region, and company.
- To identify the dominant region or segment in the global breast cancer therapeutics market.
- To identify drivers and challenges for the global breast cancer therapeutics market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the global breast cancer therapeutics market.
- To identify and analyze the profiles of leading players operating in the global breast cancer therapeutics market.
- To identify key sustainable strategies adopted by market players in global breast cancer therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the country. TechSci Research calculated the market size of the Global breast cancer therapeutics market using a top-down approach, wherein

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

**Key Target Audience:**

- Market research and consulting firms
- Government bodies such as regulating authorities and policy makers
- Organizations, forums, and alliances

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as product manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

**Report Scope:**

In this report, global breast cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

-□Breast Cancer Diagnostics Market, By Therapy:

- o□Chemotherapy
  - Anthracyclines
  - Taxanes
  - Antimetabolites
  - Others
- o□Hormone Therapy
  - Selective Estrogen Receptor Modulators
  - Aromatase Inhibitors
  - Others
- o□Immunotherapies
- o□Targeted Therapy
  - Monoclonal Antibodies
  - Tyrosine Kinase Inhibitor
  - Herceptin
  - Others
- o□Others

-□Breast Cancer Diagnostics Market, By End-User:

- o□Hospitals
- o□Specialty Clinics
- o□Ambulatory Surgical Centers
- o□Others

-□Breast Cancer Diagnostics, By Region:

- o□North America
  - United States
  - Canada
  - Mexico
- o□Asia-Pacific
  - China
  - India
  - Japan

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- South Korea
- Australia
- o□Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- o□South America
- Brazil
- Argentina
- Colombia
- o□Middle East & Africa
- Saudi Arabia
- South Africa
- UAE

#### Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global breast cancer therapeutics market.

#### Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

#### Company Information

- Detailed analysis and profiling of additional market players (up to five).

### Table of Contents:

- 1.□Product Therapy Overview
- 2.□Research Methodology
- 3.□Impact of COVID-19 on Global Breast Cancer Therapeutics Market
- 4.□Voice of Customer
- 5.□Executive Summary
- 6.□Global Breast Cancer Therapeutics Market Outlook
  - 6.1.□Market Size & Forecast
    - 6.1.1.□By Value
  - 6.2.□Market Share & Forecast
    - 6.2.1.□By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      - 6.2.1.1.□Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      - 6.2.1.2.□Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      - 6.2.1.3.□Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    - 6.2.2.□By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    - 6.2.3.□By Company (2021)
    - 6.2.4.□By Region
  - 6.3.□Product Market Map
- 7.□North America Breast Cancer Therapeutics Market Outlook
  - 7.1.□Market Size & Forecast
    - 7.1.1.□By Value
  - 7.2.□Market Share & Forecast
    - 7.2.1.□By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2.1.1.□Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
- 7.2.1.2.□Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
- 7.2.1.3.□Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
- 7.2.2.□By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 7.2.3.□By Country
- 7.3.□North America: Country Analysis
- 7.3.1.□United States Breast Cancer Therapeutics Market Outlook
- 7.3.1.1.□Market Size & Forecast
- 7.3.1.1.1.□By Value
- 7.3.1.2.□Market Share & Forecast
- 7.3.1.2.1.□By Therapy
- 7.3.1.2.2.□By End User
- 7.3.2.□Mexico Breast Cancer Therapeutics Market Outlook
- 7.3.2.1.□Market Size & Forecast
- 7.3.2.1.1.□By Value
- 7.3.2.2.□Market Share & Forecast
- 7.3.2.2.1.□By Therapy
- 7.3.2.2.2.□By End User
- 7.3.3.□Canada Breast Cancer Therapeutics Market Outlook
- 7.3.3.1.□Market Size & Forecast
- 7.3.3.1.1.□By Value
- 7.3.3.2.□Market Share & Forecast
- 7.3.3.2.1.□By Therapy
- 7.3.3.2.2.□By End User
- 8.□Europe Breast Cancer Therapeutics Market Outlook
- 8.1.□Market Size & Forecast□
- 8.1.1.□By Value
- 8.2.□Market Share & Forecast
- 8.2.1.□By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
- 8.2.1.1.□Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
- 8.2.1.2.□Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
- 8.2.1.3.□Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
- 8.2.2.□By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 8.2.3.□By Country
- 8.3.□Europe: Country Analysis
- 8.3.1.□France Breast Cancer Therapeutics Market Outlook
- 8.3.1.1.□Market Size & Forecast
- 8.3.1.1.1.□By Value
- 8.3.1.2.□Market Share & Forecast
- 8.3.1.2.1.□By Therapy
- 8.3.1.2.2.□By End User
- 8.3.2.□Germany Breast Cancer Therapeutics Market Outlook
- 8.3.2.1.□Market Size & Forecast
- 8.3.2.1.1.□By Value
- 8.3.2.2.□Market Share & Forecast
- 8.3.2.2.1.□By Therapy
- 8.3.2.2.2.□By End User

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.3.3. United Kingdom Breast Cancer Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Therapy
    - 8.3.3.2.2. By End User
- 8.3.4. Italy Breast Cancer Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Therapy
    - 8.3.4.2.2. By End User
- 8.3.5. Spain Breast Cancer Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Therapy
    - 8.3.5.2.2. By End User
- 9. Asia-Pacific Breast Cancer Therapeutics Market Outlook
  - 9.1. Market Size & Forecast
    - 9.1.1. By Value
  - 9.2. Market Share & Forecast
    - 9.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      - 9.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      - 9.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      - 9.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    - 9.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    - 9.2.3. By Country
  - 9.3. Asia-Pacific: Country Analysis
    - 9.3.1. China Breast Cancer Therapeutics Market Outlook
      - 9.3.1.1. Market Size & Forecast
        - 9.3.1.1.1. By Value
      - 9.3.1.2. Market Share & Forecast
        - 9.3.1.2.1. By Therapy
        - 9.3.1.2.2. By End User
    - 9.3.2. India Breast Cancer Therapeutics Market Outlook
      - 9.3.2.1. Market Size & Forecast
        - 9.3.2.1.1. By Value
      - 9.3.2.2. Market Share & Forecast
        - 9.3.2.2.1. By Therapy
        - 9.3.2.2.2. By End User
    - 9.3.3. Japan Breast Cancer Therapeutics Market Outlook
      - 9.3.3.1. Market Size & Forecast
        - 9.3.3.1.1. By Value
      - 9.3.3.2. Market Share & Forecast
        - 9.3.3.2.1. By Therapy
        - 9.3.3.2.2. By End User

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.3.4. South Korea Breast Cancer Therapeutics Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By Therapy
    - 9.3.4.2.2. By End User
- 9.3.5. Australia Breast Cancer Therapeutics Market Outlook
  - 9.3.5.1. Market Size & Forecast
    - 9.3.5.1.1. By Value
  - 9.3.5.2. Market Share & Forecast
    - 9.3.5.2.1. By Therapy
    - 9.3.5.2.2. By End User
- 10. South America Breast Cancer Therapeutics Market Outlook
  - 10.1. Market Size & Forecast
    - 10.1.1. By Value
  - 10.2. Market Share & Forecast
    - 10.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      - 10.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      - 10.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      - 10.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    - 10.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    - 10.2.3. By Country
  - 10.3. South America: Country Analysis
    - 10.3.1. Brazil Breast Cancer Therapeutics Market Outlook
      - 10.3.1.1. Market Size & Forecast
        - 10.3.1.1.1. By Value
      - 10.3.1.2. Market Share & Forecast
        - 10.3.1.2.1. By Therapy
        - 10.3.1.2.2. By End User
    - 10.3.2. Argentina Breast Cancer Therapeutics Market Outlook
      - 10.3.2.1. Market Size & Forecast
        - 10.3.2.1.1. By Value
      - 10.3.2.2. Market Share & Forecast
        - 10.3.2.2.1. By Therapy
        - 10.3.2.2.2. By End User
    - 10.3.3. Colombia Breast Cancer Therapeutics Market Outlook
      - 10.3.3.1. Market Size & Forecast
        - 10.3.3.1.1. By Value
      - 10.3.3.2. Market Share & Forecast
        - 10.3.3.2.1. By Therapy
        - 10.3.3.2.2. By End User
  - 11. Middle East and Africa Breast Cancer Therapeutics Market Outlook
    - 11.1. Market Size & Forecast
      - 11.1.1. By Value
    - 11.2. Market Share & Forecast
      - 11.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
        - 11.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.2.1.2.□Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
- 11.2.1.3.□Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
- 11.2.2.□By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 11.2.3.□By Country
- 11.3.□MEA: Country Analysis
- 11.3.1.□South Africa Breast Cancer Therapeutics Market Outlook
- 11.3.1.1.□Market Size & Forecast
- 11.3.1.1.1.□By Value
- 11.3.1.2.□Market Share & Forecast
- 11.3.1.2.1.□By Therapy
- 11.3.1.2.2.□By End User
- 11.3.2.□Saudi Arabia Breast Cancer Therapeutics Market Outlook
- 11.3.2.1.□Market Size & Forecast
- 11.3.2.1.1.□By Value
- 11.3.2.2.□Market Share & Forecast
- 11.3.2.2.1.□By Therapy
- 11.3.2.2.2.□By End User
- 11.3.3.□UAE Breast Cancer Therapeutics Market Outlook
- 11.3.3.1.□Market Size & Forecast
- 11.3.3.1.1.□By Value
- 11.3.3.2.□Market Share & Forecast
- 11.3.3.2.1.□By Therapy
- 11.3.3.2.2.□By End User
- 12.□Market Dynamics
- 12.1.□Drivers
- 12.2.□Challenges
- 13.□Market Trends & Developments
- 14.□Competitive Landscape
- 14.1.□Novartis AG
- 14.2.□Pfizer Inc.
- 14.3.□Eli Lilly & Company
- 14.4.□Merck Co. & Inc.
- 14.5.□GlaxoSmithKline, Plc.
- 14.6.□AstraZeneca Plc.
- 14.7.□Bristol-Myers Squibb Company
- 14.8.□Halozyme Inc.
- 14.9.□Eisai Co., Ltd.
- 14.10.□Fresenius Kabi AG
- 15.□Strategic Recommendations

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



**Breast Cancer Therapeutics Market - Global Industry Size, Share, Trends,  
Opportunity and Forecast, 2017-2027**

**Segmented By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others), By (Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others), By Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others), By Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), and By Region**

Market Report | 2022-07-01 | 75 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4900.00
	Multi-User License	\$5900.00
	Custom Research License	\$8900.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-11"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)